Nektar Therapeutics (NKTR) logo

Nektar Therapeutics (NKTR) insider trading in the last 6 months

2 insiders sold $66K. No buys.

Filings: 4, in the last 6 months
Quality Score: -10, Poor

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 4 tradesSee all 4 tradesSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Form 4 filings, newest first

SellHoward W. Robin$15KPresident & CEOat $35.85 on Nov 17, filed Nov 19
SellJonathan Zalevsky$7KChief R&D Officerat $35.85 on Nov 17, filed Nov 19
SellHoward W. Robin$30KPresident & CEOat $71.98 on Aug 18, filed Aug 20

From SEC Form 4s, the newest filed Nov 19, 2026 · Insiders have 2 business days to file a trade

Pro members see every filing on NKTR with what each insider bought or sold and at what price, and can turn on an optional alert when an insider buys.

Who files at Nektar Therapeutics

Insider trades by person

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Questions about NKTR's insider trades

As of Nov 21, 2026: Nektar Therapeutics (NKTR) has 4 insider filings on record in the last 6 months, the newest filed Nov 19, 2026. Its Quality Score is -10 (Poor). Scores as of 8:50 PM ET, 15 minutes behind.

Are NKTR insiders buying or selling?

2 insiders sold $66K across 4 filings in the last 6 months. No open-⁠market buys on record. The newest filing: Howard W. Robin, President & CEO, sold $15K on Nov 17, 2026.

Who are NKTR's biggest insider sellers?

By the dollars of their sales in the last 6 months: Howard W. Robin (President & CEO), 2 sales; Jonathan Zalevsky (Chief R&D Officer), 2 sales.

When did an NKTR insider last buy?

No NKTR insider bought shares on the open market in the last 6 months, as filed on Form 4. The newest filing is a sale by Howard W. Robin on Nov 17, 2026.

Nektar Therapeutics's page has its Quality Score, its chart, and its earnings. More in Healthcare and Biotech.

Every insider trade, with its stock's score.

Real-time prices, every Form 4 on every stock with its Quality Score, sorting, filters, and optional alerts when the people you follow file.

See the last 30 days of insider tradesSee the last 30 days of insider tradesStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Shares insiders bought or sold themselves, as filed on Form 4. Grants, option exercises, shares withheld for tax, and 10b5-1 plan sales are left out.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.